Elmiron Vision Loss Lawsuit Overview

What Is the Elmiron Lawsuit?

Thousands of women are filing lawsuits against Janssen Pharmaceuticals (a Johnson & Johnson subsidiary) alleging that the drug Elmiron caused them to develop pigmentary maculopathy — a serious retinal condition that leads to vision loss and potentially blindness.

Elmiron (generic name pentosan polysulfate sodium or PPS) is the only FDA-approved oral medication for interstitial cystitis (IC), also known as painful bladder syndrome. It has been prescribed to thousands of patients, primarily women, for decades.

The Science Behind the Claims

Research published in 2018 first linked Elmiron use to a unique form of pigmentary maculopathy — damage to the macula, the central part of the retina responsible for sharp vision:

2018 Emory University study identified a "novel maculopathy" associated with chronic Elmiron use
Subsequent studies confirmed the association across multiple patient cohorts
The longer the duration of Elmiron use, the higher the risk of maculopathy
Even patients who stopped Elmiron continued to show progression of the eye damage

In 2020, the FDA updated Elmiron's label to warn about the risk of "retinal pigmentary changes" — but plaintiffs argue this warning came too late and was insufficient.

What Is Pigmentary Maculopathy?

Pigmentary maculopathy is a condition that damages the macula and causes:

Difficulty reading
Blurred vision
Distorted vision (straight lines appearing wavy)
Dark spots in central vision
Difficulty adapting to low light
Loss of color perception
Progressive vision loss
Legal blindness in severe cases

The condition can be mistaken for age-related macular degeneration (AMD) or other eye diseases, leading to delayed diagnosis.

What Are Plaintiffs Alleging?

The lawsuits allege that Janssen Pharmaceuticals:

Knew or should have known about the eye damage risk
Failed to warn patients and doctors about the risk for years
Continued marketing Elmiron without adequate safety information
Failed to recommend regular eye monitoring for users
Delayed updating the label until 2020 despite earlier evidence
Profited from a drug with serious unwarned risks

Current Status of the Litigation

The Elmiron litigation is consolidated as MDL 2973 in the District of New Jersey, before Judge Brian R. Martinotti.

Thousands of cases pending in the MDL
Bellwether trials being prepared
No global settlement has been reached
New cases continue to be filed as more patients discover the eye damage

Why You Should Act Now

If you took Elmiron and were diagnosed with maculopathy or vision problems:

Statutes of limitations vary by state
Eye exam records documenting the diagnosis are essential
Pharmacy records showing Elmiron use are critical evidence

A free case review costs nothing. If you have vision problems after taking Elmiron, find out if you may qualify for compensation.